Kopran Limited · NSE:KOPRAN
Kopran — Q4 FY2025-26 Earnings Presentation
23 slides from Kopran's earnings presentation, May 20, 2026
Slide 1: Stock exchange filing letter for investor presentation
May 20, 2026 The Manager The Manager BSE Limited The National Stock Exchange of India Limited Corporate Relationship Department Exchange Plaza, P. J. Towers, Dalal Street, Bandra - Kurla Complex, Bandra (E), Mumbai – 400 001. Mumbai – 400 051. BSE Scrip Code No. 524280 NSE Symbol: KOPRAN Sub: Invest
Slide 2: Corporate Presentation FY 2025-26
CORPORATE PRESENTATION FY 2025-26
Slide 3: This quarterly investor presentation has been prepared by Kopran Limited (‘Kopran’) and does not
This quarterly investor presentation has been prepared by Kopran Limited (‘Kopran’) and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied, should not
Slide 4: Performance
PERFORMANCE • Financial Highlights • Operational Performance • API • Formulation
Slide 5: Financial Highlights Q4 FY 2025-26
Q-4 Q-3 Q-4 FY PARTICULARS 2025-26 2025-26 2024-25 2025-26 Revenue from Operations 23,402 19,428 17,236 68,142 EBITDA* 4,057 2,023 1,400 7,790 Finance Costs 317 267 277 1047 Forex Gain/Loss -763 -247 309 -1595 Depreciation 452 442 387 1,747 Tax Expenses 648 140 403 863 Net Profit 1,887 934 968 2,573
Slide 6: Operational Performance
OPERATIONAL PERFORMANCE
Slide 7: APIs Operational Highlights: Segment-wise Revenue Mix
APIs OPERATIONAL HIGHLIGHTS SEGMENT-WISE REVENUE MIX FY 2025-26 (Rs. in Lakhs) Q4 - FY 2025-26 (Rs. in Lakhs) 392 101 43 23 129 17 2,551 1,675 688 1149 Anti- Diabetic Anti- Diabetic 6,081 4,580 Antibiotic-Urological Anti- Infective 142 Anti-Hypertensive 1919 Antibiotic-Urological Anti-Thrombotic 151
Slide 8: APIs Operational Highlights: Market-wise Revenue Mix
APIs OPERATIONAL HIGHLIGHTS MARKET-WISE REVENUE MIX FY 2025-26 (Rs. in Lakhs) Q4 - FY 2025-26 (Rs. in Lakhs) 14598 5285 Export Sales Export Sales Local Sales Local Sales 6175 22737 Total Rs. 37,335 Lakhs Total Rs. 11,460 Lakhs
Slide 9: Formulations Operational Highlights: Region-wise Sales
Formulations OPERATIONAL HIGHLIGHTS REGION-WISE SALES BREAK-UP FY 2025-26 (Rs. in Lakhs) Q4 - FY 2025-26 (Rs. in Lakhs) 1654 984 2559 4005 Africa 943 Africa 11733 CANADA Canada Latem Latem Middle East and North Middle East and North Africa Africa South Africa South Africa Southeast Asia Southeast As
Slide 10: Formulations Operational Highlights: Product-wise Revenue Mix
Formulations OPERATIONAL HIGHLIGHTS PRODUCT-WISE REVENUE MIX FY 2025-26 (Rs. in Lakhs) Q4 - FY 2025-26 (Rs. in Lakhs) 12130 4587 Non Pen Plant Non Pen Plant Pen Plant Pen Plant 17509 6726 Total Rs. 29,639 Lakhs Total Rs. 11,313 Lakhs
Slide 11: Company Overview
Company Overview • About Us • Business Overview – API • Business Overview – Formulations • Driving Sustainable Growth
Slide 12: A Global Pharmaceutical Company
A GLOBAL PHARMACEUTICAL COMPANY An integrated Pharmaceutical Company, committed to supplying International 50+ Quality Formulations and Active Pharmaceutical Ingredients (APIs) globally. Nations - Export Reach State-of-the-art manufacturing facilities and products with various accreditations and app
Slide 13: API Vertical
API API DEDICATED AND VERSATILE PRODUCT VERTICAL FACILITIES FOR SEGMENT ❖ Anti-hypertensive ❖ Development, manufacturing and ❖ Atenolol ❖ Macrolide sale of diverse APIs and Advanced ❖ Neuromodulator Intermediates ❖ Cephalosporins - Non-Sterile & Sterile ❖ Urological ❖ One of the leaders in Atenolol
Slide 14: Formulations Vertical Product Segments
FORMULATIONS PRODUCT SEGMENTS FORMULATIONS VERTICAL ❖ Development and manufacturing of oral solid dosages and dry powder formulations for both Penicillin- and Non-Penicillin-based drugs PENICILLIN-BASED NON-PENICILLIN FINISHED ORAL BASED FINISHED ❖ Catering 100% export markets of both Regulated and
Slide 15: Strategic Imperatives
STRATEGIC IMPERATIVES GROWTH AND SUSTAINABILITY COST LEADERSHIP ❖ Focus on R&D to develop niche, ❖ Development of intermediates for APIs high-value/high-volume APIs and intermediates ❖ Reducing dependence on China to move towards self sufficiency ❖ Capacity expansion ❖ Optimising operational cost ❖
Slide 16: Regulatory Compliance
REGULATORY COMPLIANCE OFFERING BEST-IN-CLASS QUALITY THROUGH STRICT COMPLIANCE The Company maintains highest global regulatory standards FORMULATIONS ACCREDITATIONS of manufacturing and quality at its all plants API ACCREDITATIONS Approved by 15 countries including MHRA (UK), SAPHRA South The plant
Slide 17: Scheme of Amalgamation with Kopran Laboratories Ltd.
The Board of Directors of Kopran Limited and Kopran Laboratories Limited in their Board Meetings held on 20th March, 2025 and subsequently on 8th August, 2025 have subject to the approval of Stock Exchanges, shareholders, National Company Law Tribunal (NCLT) and other relevant Authorities, proposed
Slide 18: Financial Performance
FINANCIAL <—, PERFORMANCE Kopran
Slide 19: Snapshot
SNAPSHOT EBITDA * (Rs. in LAKHS) SALES/OTHER INCOME (Rs. in LAKHS) 8,739 68,177 8,178 7,790 62,920 63,359 7,441 7,290 55,405 50,980 48,813 5,180 36,013 4,696 2019-20 2020-21 2021-22 2022-23 2023-24 2024-25 2025-26 2019-20 2020-21 2021-22 2022-23 2023-24 2024-25 2025-26 FINANCE COSTS (Rs. in LAKHS) N
Slide 20: Building Shareholder Value Year on Year
BUILDING SHAREHOLDER VALUE YEAR ON YEAR EBITDA ( Rs. in Lakhs) RoE ( % ) RoCE ( % ) 28.3 8,739 25.3 22.4 8,178 7,790 7,441 7,290 20.1 14.5 5,180 4,696 11.8 11.5 9.4 8.4 9.2 11 6.3 7.6 4.9 2019-20 2020-21 2021-22 2022-23 2023-24 2024-25 2025-26 2019-20 2020-21 2021-22 2022-23 2023-24 2024-25 2025-26
Slide 21: Seven-year financial summary
(Rs. in Lakhs) PARTICULARS FY FY FY FY FY FY FY 2025-26 2024-25 2023-24 2022-23 2021-22 2020-21 2019-20 Equity Share Capital 4,829 4,829 4,821 4,821 4,821 4,325 4,325 Other Equity 48,199 47,006 44,303 39,104 37,796 20,178 14,643 Net Worth 53,028 51,835 49,125 43,925 42,617 24,503 18,968 Fixed Assets
Slide 22: Board of Directors
BOARD OF DIRECTORS MR. SURENDRA SOMANI MR. VARUN SURENDRA SOMANI MRS. NAMRATA SOMANI CHAIRMAN & MANAGING DIRECTOR DIRECTOR DIRECTOR MR. CHANDRESH GANDHI MRS. MAMTA BIYANI MR. NARAYAN ATAL INDEPENDENT DIRECTOR INDEPENDENT DIRECTOR INDEPENDENT DIRECTOR
Slide 23: About Kopran Limited
ABOUT KOPRAN LIMITED: Kopran Limited is an integrated Pharmaceutical Company, committed to manufacturing and supplying International Quality Formulations and APIs worldwide. Kopran's manufacturing facilities and products have accreditations across all the continents. Research & Development for New P